# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Fortress Biotech (NASDAQ:FBIO) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(1....
Alliance Global Partners initiates coverage on Fortress Biotech (NASDAQ:FBIO) with a Buy rating and announces Price Target of...
Roth MKM analyst Jason Wittes reinstates Fortress Biotech (NASDAQ:FBIO) with a Buy and announces $10 price target.
Half of the enrolled patients had stable disease for at least two months, two showed partial response and two experienced com...
$1.5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
The CNN Money Fear and Greed index showed some decline in overall market sentiment, but the index remained in the "Extreme ...